AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval

17 Jun 2024
www.pharmaceutical-technology.com
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval
Preview
Source: Pharmaceutical Technology
In a Phase III trial, AstraZeneca’s Imfinzi plus chemotherapy -reduced disease progression or death risk by 58% in endometrial cancer patients. Credit: Anna in Sweden / Shutterstock.
AstraZeneca‘s Imfinzi (durvalumab), in combination with chemotherapy, has received approval from the US Food and Drug Administration (FDA) for treating adults with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR).
The treatment regimen comprises Imfinzi plus chemotherapy including carboplatin and paclitaxel, followed by Imfinzi monotherapy.
This approval from the FDA is based on a subgroup analysis from the DUO-E Phase III trial, which focused on MMR status.
The randomised, multicentre, double-blind, placebo-controlled study assessed Imfinzi plus platinum-based chemotherapy followed by either Imfinzi monotherapy or Imfinzi plus Lynparza (olaparib), against chemotherapy alone.
It included 699 patients with newly diagnosed advanced or recurrent epithelial endometrial carcinoma.
See Also:FDA grants approval for Alexion’s NMOSD treatment
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval
Preview
Source: Pharmaceutical Technology
AbbVie signs agreement to acquire Landos Biopharma for $212.5m
AstraZeneca Imfinzi regimen for endometrial cancer gains FDA approval
Preview
Source: Pharmaceutical Technology
Patients in the trial were randomised to receive Imfinzi or a placebo every three weeks, alongside platinum-based chemotherapy.
Results showed that the Imfinzi combination regimen reduced the risk of disease progression or death by 58% in patients versus chemotherapy alone.
Imfinzi and chemotherapy regimen’s safety profile was found to be generally manageable and well-tolerated, aligning with outcomes from previous trials without any new safety concerns.
The Lynparza and Imfinzi arm also met the trial’s primary endpoint of progression-free survival (PFS).
Regulatory submissions for the Imfinzi and Lynparza regimens are currently under review in regions and countries including the European Union and Japan, drawing from the data from the DUO-E trial.
AstraZeneca oncology business unit executive vice-president Dave Fredrickson stated: “There have been limited advances in the treatment of endometrial cancer in the last few decades, and continued innovation is critical as the burden of this cancer is expected to grow in the future.
“Immunotherapy in combination with chemotherapy is emerging as a new standard of care in this setting, and the approval of Imfinzi offers an important new option for patients with mismatch repair deficient disease.”
The latest development comes after the FDA approved AstraZeneca‘s Farxiga (dapagliflozin) for the treatment of paediatric patients aged 10 years and above with type-2 diabetes.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
[+3]
Indications
[+1]
Targets
-
Drugs
[+2]
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.